Treatment of actinic keratosis: a systematic review
Arch Dermatol Res. 2022 Dec 1. doi: 10.1007/s00403-022-02490-5. Online ahead of print.ABSTRACTTreatment of actinic keratoses (AKs) can help lower the risk of eventual skin cancer and address field pre-cancerization. This review compares the different therapeutic options for actinic keratosis. Databases used include Medline, EMBASE, Web of Science and the Cochrane Library from inception to December 2019. Randomized control trials that were related to any approved or recognized treatment for actinic keratosis were included. 1186 studies were found, of which 80 with 6748 patients were included in the analysis. A network meta-...
Source: Cancer Control - December 1, 2022 Category: Cancer & Oncology Authors: Brandon Worley Vishnu Harikumar Kelly Reynolds McKenzie A Dirr Rachel E Christensen Noor Anvery Michael D Yi Emily Poon Murad Alam Source Type: research
SA33 Demographic Characteristics of Patients Initiating Topical Combination Therapies for Plaque Psoriasis in Canada: A Claims-Based Analysis
This study aims to describe the demographic characteristics of Canadian patients who initiated one of the topical combination products following the notice of compliance issued by Health Canada for HP/TAZ in 2020. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: V Gaudet, H Yang, T Bourgoin, A Sharma, M Barbeau Source Type: research
Treatment of actinic keratosis: a systematic review
AbstractTreatment of actinic keratoses (AKs) can help lower the risk of eventual skin cancer and address field pre-cancerization. This review compares the different therapeutic options for actinic keratosis. Databases used include Medline, EMBASE, Web of Science and the Cochrane Library from inception to December 2019. Randomized control trials that were related to any approved or recognized treatment for actinic keratosis were include d. 1186 studies were found, of which 80 with 6748 patients were included in the analysis. A network meta-analysis was not possible due to interstudy heterogeneity. The greatest degree of ...
Source: Archives of Dermatological Research - December 1, 2022 Category: Dermatology Source Type: research
021 IL-4 Receptor α Blockade Attenuates Allergic Conjunctivitis in a Novel Murine Ocular Model
Conjunctivitis, a common comorbidity in atopic dermatitis (AD), occurs at an increased frequency in AD patients given treatments that target interleukin-4 receptor alpha (IL-4R α) or IL-13. However, the mechanisms driving this development of conjunctivitis remain unknown for AD. Wild-type BALB/c mice were treated epicutaneously with MC903 (calcipotriol)+ ovalbumin (OVA) to evoke AD-like disease and challenged ocularly with OVA or with vehicle control (phosphate-buffered s aline [PBS]) once daily for 7 days. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - November 18, 2022 Category: Dermatology Authors: H. Han, K.C. Shade, J. Gans, A. Hicks Source Type: research
378 Ultraviolet radiation-induced antimicrobials neutralize S. aureus and reduce atopic dermatitis-associated inflammation
Atopic dermatitis (AD) is a common inflammatory skin disease with increased colonization by pathogenic Staphylococcus aureus, which has been linked to production of abnormal levels of antimicrobial peptides (AMPs) in AD skin. Ultraviolet radiation (UVR) phototherapy is a widely used treatment for AD. We hypothesize that the efficacy of phototherapy in AD patients depends on the ability of UVR to (re)induce the expression of AMPs from host skin and normalize dysbiotic S. aureus colonization. To test this hypothesis, we developed a new mouse model of AD by treating the skin with calcipotriol (MC903) and an S. (Source: Journa...
Source: Journal of Investigative Dermatology - November 18, 2022 Category: Dermatology Authors: V. Patra, A. Cornu, C. Badiou, G. Lina, J. Nicolas, P. Wolf, M. Vocanson Source Type: research
No Adverse Effects on Periarticular Tissue by Intra-articular Vitamin D analogue Calcipotriol in a Reduced-Dose Zymosan-Induced Arthritis Model in Rats
Basic Clin Pharmacol Toxicol. 2022 Nov 18. doi: 10.1111/bcpt.13815. Online ahead of print.ABSTRACTCalcipotriol, a vitamin D analogue, is an antiproliferative and anti-inflammatory drug currently used in psoriasis. Here, our aim was to analyse the safety of calcipotriol for cartilage and bone in alleviated-dose (0.1mg instead of usual ≥1mg dose) zymosan-induced arthritis in rats. Theoretically, high doses of vitamin D or analogues could have detrimental effects on bone or cartilage. The rats were divided into four groups: vehicle (n=9), dexamethasone 0.1 mg/kg (n=9), calcipotriol 0.1 mg/kg (n=8) and negative control (n=10...
Source: Cancer Control - November 18, 2022 Category: Cancer & Oncology Authors: Jere Huovinen Jesse Lohela Sami Kauppinen Mikko Finnil ä Sakari Laaksonen Hanna-Marja Voipio Johanna A Huhtakangas Petri Lehenkari Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
